Three-month treatment outcome of medication-overuse headache according to classes of overused medications, use of acute medications, and preventive treatments
- PMID: 38992145
- PMCID: PMC11239667
- DOI: 10.1038/s41598-024-66906-0
Three-month treatment outcome of medication-overuse headache according to classes of overused medications, use of acute medications, and preventive treatments
Abstract
Medication overuse headache (MOH) is a chronic headache disorder that results from excessive use of acutely symptomatic headache medications, leading to more frequent and severe headaches. This study aims to assess the 3-month treatment outcomes in MOH patients, focusing on the types and usage of overused medications, as well as preventive treatments. This prospective cross-sectional study analyzed the treatment outcomes of 309 MOH patients from April 2020 to March 2022. Patients were advised to discontinue overused medications immediately and offered preventive treatments based on clinical judgment. Data on headache characteristics, medication use, and impact on daily life were collected at baseline and 3 months. Results showed overall significant improvements in headache-related variables in patients completing the 3-month treatment follow-up. The median number of headache days per month decreased from 15 days at baseline to 8 days after 3 months (p < 0.001). Patients who overused multiple drug classes demonstrated increased disability levels (mean Headache Impact Test-6 score: 62 at baseline vs. 56 at 3 months, p < 0.01). Those who continued overusing medications reported more days of severe headache (mean 18 days at baseline vs. 14 days at 3 months, p < 0.05) and greater impact (mean Migraine Disability Assessment score: 35 at baseline vs. 28 after 3 months, p < 0.05) compared to the baseline. Differences in headache outcomes were evident across different preventive treatment groups, with generalized estimating equation analyses highlighting significant associations between clinical characteristics, overused medication classes, and preventive treatments. Most MOH clinical features significantly improved after 3 months of treatment. However, notable interactions were observed with certain clinical presentations, suggesting possible influences of overused medication classes, usage patterns, and preventive treatment types on MOH treatment outcomes. This study underscores the importance of individualized treatment strategies and the potential benefits of discontinuing overused medications.
Keywords: Chronic headache; Medication-overuse headache; Migraine; Three-month follow-up; Treatment strategies.
© 2024. The Author(s).
Conflict of interest statement
MKC was a site investigator for a multicenter trial sponsored by Biohaven Pharmaceuticals, Allergan Korea, and Ildong Pharmaceutical Company. He received lecture honoraria from Eli Lilly and Company, Handok-Teva, and Ildong Pharmaceutical Company over the past 24 months. He received Grants from Yonsei University College of Medicine (6-2021-0229), the Korea Health Industry Development Institute (KHIDI) (HV22C0106), and a National Research Foundation of Korea (NRF) Grant from the Korean government (MSIT) (2022R1A2C1091767). The other authors declare no conflicts of interest.
Figures

Similar articles
-
Clinical characteristics of medication-overuse headache according to the class of acute medication: A cross-sectional multicenter study.Headache. 2022 Jul;62(7):890-902. doi: 10.1111/head.14363. Epub 2022 Jul 14. Headache. 2022. PMID: 35833500
-
Comparing Two Ways to Manage Symptoms for Patients Who Have Chronic Migraine and Frequent Medication Use – The MOTS Trial [Internet].Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2022 Feb. Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2022 Feb. PMID: 39432696 Free Books & Documents. Review.
-
Patient-Centered Treatment of Chronic Migraine With Medication Overuse: A Prospective, Randomized, Pragmatic Clinical Trial.Neurology. 2022 Apr 5;98(14):e1409-e1421. doi: 10.1212/WNL.0000000000200117. Epub 2022 Feb 15. Neurology. 2022. PMID: 35169011 Clinical Trial.
-
Medication-overuse headache.Continuum (Minneap Minn). 2012 Aug;18(4):807-22. doi: 10.1212/01.CON.0000418644.32032.7b. Continuum (Minneap Minn). 2012. PMID: 22868543 Review.
-
Headache characteristics and burden from chronic migraine with medication overuse headache: Cross-sectional observations from the Medication Overuse Treatment Strategy trial.Headache. 2021 Feb;61(2):351-362. doi: 10.1111/head.14056. Epub 2021 Jan 12. Headache. 2021. PMID: 33432635 Clinical Trial.
Cited by
-
Reduction of neck pain severity in patients with medication-overuse headache.J Headache Pain. 2024 Nov 4;25(1):190. doi: 10.1186/s10194-024-01876-2. J Headache Pain. 2024. PMID: 39497031 Free PMC article.
-
Differences in Patient-Physician Satisfaction for Migraine Treatment Medications in Patients with and without Medication-Overuse Headache: A Cross-Sectional Real-World Survey.Neurol Ther. 2025 Aug 19. doi: 10.1007/s40120-025-00812-z. Online ahead of print. Neurol Ther. 2025. PMID: 40826258
References
-
- Peters, G. A. & Horton, B. T. In Proceedings of the staff meetings. Mayo Clinic. pp. 153–161. - PubMed
-
- Committee C. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8:1–96. - PubMed
-
- Society, H. C. S. o. t. I. H. The International Classification of Headache Disorders: 2nd edition. Cephalalgia75, 808–811 (2004). - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous